Actionable news
All posts from Actionable news
Actionable news in PGNX: Progenics Pharmaceuticals Inc.,

Progenics Pharmaceuticals: 777 Old Saw Mill River Road

The following excerpt is from the company's SEC filing.

Tarrytown, New York 10591

Fax: (914) 789-2817

(914) 789-2800

Data from Phase 2 Study of Progenics' 1404 Imaging Agent Presented

at EANM Congress 2015

- Uptake Associated with Gleason Score Upgrade/Downgrade Following Radical Prostatectomy -

– Progenics Pharmaceuticals, Inc., (Nasdaq: PGNX) today announced the presentation of additional data from a Phase 2 trial of its PSMA-targeted imaging agent candidate, 1404, at the 28

Annual European Association of Nuclear Medicine (EANM) Congress being held in H amburg, Germany. 1404 is a prostate specific membrane antigen (PSMA) targeted small molecule labeled with technetium-99m designed to "visualize" prostate cancer.

Results from the Phase 2 trial in high-risk patients undergoing radical prostatectomy were presented by Professor Karolien Goffin, M.D., Ph.D., University Hospitals Leuven, and included previously reported sensitivity and accuracy data for 1404 and data related to the uptake of 1404 in the lobes of the prostate gland. New data presented at the meeting demonstrate that 1404 uptake in the prostate gland is significantly higher in prostate cancer patients with upgraded Gleason scores at radical prostatectomy from those who are downgraded at radical prostatectomy.

"The data presented demonstrate the potential of 1404 to better assess the stage and extent of a patient's prostate cancer versus biopsy, as confirmed by comparison with histopathology, the truth standard

obtained from radical prostatectomy

stated Dr. Goffin.

In the Phase 2 study, 31% (25/81) of evaluable patients had their biopsy Gleason score upgraded to >7 or downgraded to

7 by histopathologic assessment of the prostatectomy specimen. Of patients upgraded to a Gleason score >7, 79% (11/14) demonstrated high lesion uptake of 1404 with a mean tumor to background ratio (TBR) of 47:1. Of patients downgraded to Gleason score

7, 91% (10/11) had significantly (p<0.001) lower lesion uptake of 1404 with a mean TBR of 16:1.

About 1404, an Imaging Compound Targeting Prostate Specific Membrane Antigen

Progenics' molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate...